Actively Recruiting
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
Led by Viome · Updated on 2025-01-29
30
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
Sponsors
V
Viome
Lead Sponsor
A
AdventHealth
Collaborating Sponsor
AI-Summary
What this Trial Is About
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.
CONDITIONS
Official Title
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult females > 18 years old
- Diagnosed with advanced or recurrent gynecological cancer
- Scheduled to receive an immunotherapy regimen
- Patients recruited from AHMG AdventHealth Orlando Gynecologic Oncology Group
You will not qualify if you...
- Unable to provide fecal specimens at three required time points
- Unable to read or understand informed consent
- Taking medications that affect gut microbiome, including proton pump inhibitors, metformin, antibiotics, or laxatives
- Currently receiving any investigational agent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
AdventHealth Cancer Institute
Orlando, Florida, United States, 32804
Actively Recruiting
Research Team
M
Momchilo Vuyisich, PhD
CONTACT
R
Ryan Toma, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here